Neurocrine Biosciences, Inc. revenue by segment NBIX

Neurocrine Biosciences, Inc. splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Product at $1.1 billion, 100% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Sep 30, 2026
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Revenue
3,702
1,123
959
814
806
795
688
573
628
Product
3,683
+38.6%
share 99.5%
1,119
+41.7%
share 99.7%
954
+39.9%
share 99.5%
811
+43.9%
share 99.6%
798
+28.5%
share 99.1%
790
share 99.4%
682
share 99.2%
564
share 98.4%
621
share 99.0%
Collaboration Revenue
19
-26.3%
share 0.5%
4
-26.0%
share 0.3%
5
-14.5%
share 0.5%
4
-60.7%
share 0.4%
7
+10.8%
share 0.9%
5
share 0.6%
6
share 0.8%
9
share 1.6%
6
share 1.0%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
NBIX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
Large accelerated filer
SEC CIK
914475

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.